Phase IB Study of Personalized Ultrahypofractionated Stereotactic Ablative Radiotherapy of High Risk PROstate Cancer Guided by PET PSMA (68Ga PMSA-11; Ilucix) Response (PULSAR ProPhet)
Latest Information Update: 29 Mar 2024
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PULSAR ProPhet
Most Recent Events
- 08 Mar 2024 Status changed from not yet recruiting to recruiting.
- 19 Dec 2023 Planned initiation date changed from 1 Nov 2023 to 1 Feb 2024.
- 14 Nov 2023 New trial record